Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) and Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.
Profitability
This table compares Corvus Pharmaceuticals and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Corvus Pharmaceuticals | N/A | -70.71% | -45.90% |
| Enanta Pharmaceuticals | -160.27% | -63.75% | -27.09% |
Risk & Volatility
Corvus Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Corvus Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
| Enanta Pharmaceuticals | 1 | 0 | 2 | 1 | 2.75 |
Corvus Pharmaceuticals presently has a consensus target price of $12.83, indicating a potential upside of 43.39%. Enanta Pharmaceuticals has a consensus target price of $19.67, indicating a potential upside of 110.56%. Given Enanta Pharmaceuticals’ higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Corvus Pharmaceuticals.
Earnings & Valuation
This table compares Corvus Pharmaceuticals and Enanta Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Corvus Pharmaceuticals | N/A | N/A | -$27.03 million | ($0.93) | -9.62 |
| Enanta Pharmaceuticals | $79.20 million | 2.50 | -$133.82 million | ($5.45) | -1.71 |
Corvus Pharmaceuticals has higher earnings, but lower revenue than Enanta Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Corvus Pharmaceuticals beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
